Aptus Pharma to Raise ₹44.88 Cr for Manufacturing, Expansion

Aptus Pharma Limited is charting its next growth phase by focusing on developing its own manufacturing capabilities, strengthening its Pan-India presence, and exploring international markets. The company plans to raise ₹44.88 crore through a preferential issue of equity shares, subject to shareholder approval at the AGM on September 14, 2026. Funds will be allocated to capital expenditure (₹25 crore), working capital (₹10 crore), and general corporate purposes (₹9.88 crore). The long-term strategy includes meeting approximately 20% of product requirements through in-house manufacturing, expanding domestic sales and distribution, and exploring markets in Africa, the Middle East, and Latin America.